Browse > Article
http://dx.doi.org/10.5223/pghn.2015.18.4.230

Maladaptive Behavior and Gastrointestinal Disorders in Children with Autism Spectrum Disorder  

Pusponegoro, Hardiono D. (Department of Child Health, Medical School, University of Indonesia)
Ismael, Sofyan (Department of Child Health, Medical School, University of Indonesia)
Sastroasmoro, Sudigdo (Department of Child Health, Medical School, University of Indonesia)
Firmansyah, Agus (Department of Child Health, Medical School, University of Indonesia)
Vandenplas, Yvan (Department of Pediatrics, Universitair Ziekenhuis Brussel)
Publication Information
Pediatric Gastroenterology, Hepatology & Nutrition / v.18, no.4, 2015 , pp. 230-237 More about this Journal
Abstract
Purpose: Various gastrointestinal factors may contribute to maladaptive behavior in children with autism spectrum disorders (ASD). To determine the association between maladaptive behavior in children with ASD and gastrointestinal symptoms such as severity, intestinal microbiota, inflammation, enterocyte damage, permeability and absorption of opioid peptides. Methods: This observational cross-sectional study compared children with ASD to healthy controls, aged 2-10 years. Maladaptive behavior was classified using the Approach Withdrawal Problems Composite subtest of the Pervasive Developmental Disorder Behavior Inventory. Dependent variables were gastrointestinal symptom severity index, fecal calprotectin, urinary D-lactate, urinary lactulose/mannitol excretion, urinary intestinal fatty acids binding protein (I-FABP) and urinary opioid peptide excretion. Results: We did not find a significant difference between children with ASD with severe or mild maladaptive behavior and control subjects for gastrointestinal symptoms, fecal calprotectin, urinary D-lactate, and lactulose/mannitol ratio. Urinary opioid peptide excretion was absent in all children. Children with ASD with severe maladaptive behavior showed significantly higher urinary I-FABP levels compared to those with mild maladaptive behavior (p=0.019) and controls (p=0.015). Conclusion: In our series, maladaptive behavior in ASD children was not associated with gastrointestinal symptoms, intestinal inflammation (no difference in calprotectin), microbiota (no difference in urinary D-lactate) and intestinal permeability (no difference in lactulose/manitol ratio). ASD children with severe maladaptive behavior have significantly more enterocyte damage (increased urinary I-FABP) than ASD children with mild maladaptive behavior and normal children.
Keywords
Autism spectrum disorder; Intestinal inflammation; Intestinal permeability; Enterocyte damage; Urinary opioids;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Steyaert JG, De la Marche W. What's new in autism? Eur J Pediatr 2008;167:1091-101.   DOI
2 Autism and Developmental Disabilities Monitoring Network Surveillance Year 2008 Principal Investigators; Centers for Disease Control and Prevention. Prevalence of autism spectrum disorders--Autism and Developmental Disabilities Monitoring Network, 14 sites, United States, 2008. MMWR Surveill Summ 2012;61:1-19.
3 Stilp RL, Gernsbacher MA, Schweigert EK, Arneson CL, Goldsmith HH. Genetic variance for autism screening items in an unselected sample of toddler-age twins. J Am Acad Child Adolesc Psychiatry 2010;49:267-76.
4 Hertz-Picciotto I, Croen LA, Hansen R, Jones CR, van de Water J, Pessah IN. The CHARGE study: an epidemiologic investigation of genetic and environmental factors contributing to autism. Environ Health Perspect 2006;114:1119-25.   DOI
5 Currenti SA. Understanding and determining the etiology of autism. Cell Mol Neurobiol 2010;30:161-71.   DOI
6 Smith RA, Farnworth H, Wright B, Allgar V. Are there more bowel symptoms in children with autism compared to normal children and children with other developmental and neurological disorders?: A case control study. Autism 2009;13:343-55.   DOI
7 Gorrindo P, Williams KC, Lee EB, Walker LS, McGrew SG, Levitt P. Gastrointestinal dysfunction in autism: parental report, clinical evaluation, and associated factors. Autism Res 2012;5:101-8.   DOI
8 Ibrahim SH, Voigt RG, Katusic SK, Weaver AL, Barbaresi WJ. Incidence of gastrointestinal symptoms in children with autism: a population-based study. Pediatrics 2009;124:680-6.   DOI
9 Mouridsen SE, Rich B, Isager T. A longitudinal study of gastrointestinal diseases in individuals diagnosed with infantile autism as children. Child Care Health Dev 2010;36:437-43.   DOI
10 Reichelt KL, Knivsberg AM. Can the pathophysiology of autism be explained by the nature of the discovered urine peptides? Nutr Neurosci 2003;6:19-28.   DOI
11 Handen BL, Melmed RD, Hansen RL, Aman MG, Burnham DL, Bruss JB, et al. A double-blind, placebo- controlled trial of oral human immunoglobulin for gastrointestinal dysfunction in children with autistic disorder. J Autism Dev Disord 2009;39:796-805.   DOI
12 Chaidez V, Hansen RL, Hertz-Picciotto I. Gastrointestinal problems in children with autism, developmental delays or typical development. J Autism Dev Disord 2014;44:1117-27.   DOI
13 Wang LW, Tancredi DJ, Thomas DW. The prevalence of gastrointestinal problems in children across the United States with autism spectrum disorders from families with multiple affected members. J Dev Behav Pediatr 2011;32:351-60.   DOI
14 Kemperman RF, Muskiet FD, Boutier AI, Kema IP, Muskiet FA. Brief report: normal intestinal permeability at elevated platelet serotonin levels in a subgroup of children with pervasive developmental disorders in Curacao (The Netherlands antilles). J Autism Dev Disord 2008;38:401-6.   DOI
15 American Psychiatric Association. Diagnostic and statistical manual of mental disorders IV-TR. Washington DC: American Psychiatric Association; 2000.
16 Cohen IL, Sudhalter V. PDD behavior inventory. Professional manual. Florida: Psychological Assessment Resources, Inc.; 2005.
17 Centers for Disease Control and Prevention, National Center for Health Statistics. Clinical Growth Chart: United States [Internet]. Atlanta (GA): Centers for Disease Control and Prevention; 2000 [cited 2012 June 1]. Available from: http://www.cdc.gov/growthcharts.
18 Sjarif DR, Lestari ED, Mexitalia M, Nasar SS. Textbook of pediatric nutrition and metabolic diseases. Jakarta: Indonesian Pediatric Society; 2011:36-48.
19 Vreugdenhil AC, Wolters VM, Adriaanse MP, Van den Neucker AM, van Bijnen AA, Houwen R, et al. Additional value of serum I-FABP levels for evaluating celiac disease activity in children. Scand J Gastroenterol 2011;46:1435-41.   DOI
20 Waterlow JC. Classification and definition of protein- calorie malnutrition. Br Med J 1972;3:566-9.   DOI
21 Grootjans J, Thuijls G, Verdam F, Derikx JP, Lenaerts K, Buurman WA. Non-invasive assessment of barrier integrity and function of the human gut. World J Gastrointest Surg 2010;2:61-9.
22 Dettmer K, Hanna D, Whetstone P, Hansen R, Hammock BD. Autism and urinary exogenous neuropeptides: development of an on-line SPE-HPLC-tandem mass spectrometry method to test the opioid excess theory. Anal Bioanal Chem 2007;388:1643-51.   DOI
23 Jackson PB, Boccuto L, Skinner C, Collins JS, Neri G, Gurrieri F, et al. Further evidence that the rs1858830 C variant in the promoter region of the MET gene is associated with autistic disorder. Autism Res 2009;2:232-6.   DOI
24 Campbell DB, Buie TM, Winter H, Bauman M, Sutcliffe JS, Perrin JM, et al. Distinct genetic risk based on association of MET in families with co-occurring autism and gastrointestinal conditions. Pediatrics 2009;123:1018-24.   DOI
25 Savino F, Castagno E, Calabrese R, Viola S, Oggero R, Miniero R. High faecal calprotectin levels in healthy, exclusively breast-fed infants. Neonatology 2010;97:299-304.   DOI
26 Prell C, Nagel D, Freudenberg F, Schwarzer A, Koletzko S. Comparison of three tests for faecal calprotectin in children and young adults: a retrospective monocentric study. BMJ Open 2014;4:e004558.   DOI
27 Gondalia SV, Palombo EA, Knowles SR, Cox SB, Meyer D, Austin DW. Molecular characterisation of gastrointestinal microbiota of children with autism (with and without gastrointestinal dysfunction) and their neurotypical siblings. Autism Res 2012;5:419-27.   DOI
28 Fernell E, Fagerberg UL, Hellstrom PM. No evidence for a clear link between active intestinal inflammation and autism based on analyses of faecal calprotectin and rectal nitric oxide. Acta Paediatr 2007;96:1076-9.   DOI
29 Buie T, Campbell DB, Fuchs GJ 3rd, Furuta GT, Levy J, Vandewater J, et al. Evaluation, diagnosis, and treatment of gastrointestinal disorders in individuals with ASDs: a consensus report. Pediatrics 2010;125 Suppl 1:S1-18.   DOI
30 de Magistris L, Familiari V, Pascotto A, Sapone A, Frolli A, Iardino P, et al. Alterations of the intestinal barrier in patients with autism spectrum disorders and in their first-degree relatives. J Pediatr Gastroenterol Nutr 2010;51:418-24.   DOI
31 Boaz RT, Joseph AJ, Kang G, Bose A. Intestinal permeability in normally nourished and malnourished children with and without diarrhea. Indian Pediatr 2013;50:152-3.   DOI
32 Cass H, Gringras P, March J, McKendrick I, O'Hare AE, Owen L, et al. Absence of urinary opioid peptides in children with autism. Arch Dis Child 2008;93:745-50.   DOI
33 MacFabe DF. Enteric short-chain fatty acids: microbial messengers of metabolism, mitochondria, and mind: implications in autism spectrum disorders. Microb Ecol Health Dis 2015;26:28177.